Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
0.8749
USD
|
+1.72%
|
|
+1.82%
|
+0.56%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
7,695
|
1,901
|
1,333
|
488.6
|
355.2
|
359.3
|
-
|
-
|
Enterprise Value (EV)
1 |
7,101
|
1,400
|
1,114
|
270.4
|
156
|
141.8
|
172.8
|
327.3
|
P/E ratio
|
-306
x
|
-97.8
x
|
169
x
|
-4.65
x
|
-5.8
x
|
-5.87
x
|
-6.54
x
|
87.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
17.9
x
|
3.1
x
|
2.29
x
|
1.32
x
|
1.16
x
|
1.61
x
|
1.55
x
|
1.2
x
|
EV / Revenue
|
16.5
x
|
2.28
x
|
1.91
x
|
0.73
x
|
0.51
x
|
0.63
x
|
0.75
x
|
1.1
x
|
EV / EBITDA
|
-295
x
|
-73.5
x
|
44.9
x
|
-5.69
x
|
-2.31
x
|
-1.94
x
|
-2.55
x
|
-191
x
|
EV / FCF
|
-600
x
|
-63.7
x
|
-16.7
x
|
-1.5
x
|
22.7
x
|
6.75
x
|
-
|
-
|
FCF Yield
|
-0.17%
|
-1.57%
|
-5.97%
|
-66.8%
|
4.41%
|
14.8%
|
-
|
-
|
Price to Book
|
12.1
x
|
2.97
x
|
2
x
|
0.82
x
|
0.64
x
|
0.72
x
|
0.78
x
|
-
|
Nbr of stocks (in thousands)
|
358,907
|
388,829
|
395,629
|
403,829
|
408,292
|
410,672
|
-
|
-
|
Reference price
2 |
21.44
|
4.890
|
3.370
|
1.210
|
0.8700
|
0.8749
|
0.8749
|
0.8749
|
Announcement Date
|
2/25/20
|
2/25/21
|
3/1/22
|
3/1/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
429.8
|
614.1
|
583.2
|
369.2
|
306.9
|
223.8
|
231.2
|
298.4
|
EBITDA
1 |
-24.1
|
-19.06
|
24.81
|
-47.5
|
-67.43
|
-73.02
|
-67.66
|
-1.71
|
EBIT
1 |
-24.28
|
-19.66
|
24.22
|
-74.26
|
-67.59
|
-53.12
|
-24.45
|
36.98
|
Operating Margin
|
-5.65%
|
-3.2%
|
4.15%
|
-20.12%
|
-22.02%
|
-23.73%
|
-10.57%
|
12.39%
|
Earnings before Tax (EBT)
1 |
-22.48
|
-17.26
|
11.29
|
-103.8
|
-53.67
|
-54.88
|
-36.64
|
38.41
|
Net income
1 |
-22.64
|
-18
|
7.729
|
-105.8
|
-59.11
|
-60.6
|
-52.6
|
3.706
|
Net margin
|
-5.27%
|
-2.93%
|
1.33%
|
-28.66%
|
-19.26%
|
-27.08%
|
-22.75%
|
1.24%
|
EPS
2 |
-0.0700
|
-0.0500
|
0.0200
|
-0.2600
|
-0.1500
|
-0.1490
|
-0.1338
|
0.0100
|
Free Cash Flow
1 |
-11.84
|
-22
|
-66.53
|
-180.7
|
6.88
|
21
|
-
|
-
|
FCF margin
|
-2.76%
|
-3.58%
|
-11.41%
|
-48.94%
|
2.24%
|
9.38%
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/25/20
|
2/25/21
|
3/1/22
|
3/1/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
142
|
144.5
|
94.63
|
94.44
|
89.88
|
90.24
|
85.98
|
80.17
|
66.06
|
74.71
|
57.05
|
54.56
|
52.81
|
57.32
|
EBITDA
|
1.186
|
15.88
|
-27.53
|
-37.48
|
-5.006
|
-3.029
|
-17.28
|
-
|
-
|
-4.804
|
-
|
-
|
-
|
-
|
EBIT
1 |
1.042
|
15.74
|
-28.31
|
-37.62
|
1.427
|
-9.766
|
-17.34
|
-23.96
|
-21.45
|
-4.837
|
-11.78
|
-13.32
|
-14.66
|
-13.35
|
Operating Margin
|
0.73%
|
10.89%
|
-29.91%
|
-39.83%
|
1.59%
|
-10.82%
|
-20.17%
|
-29.89%
|
-32.47%
|
-6.47%
|
-20.66%
|
-24.41%
|
-27.76%
|
-23.29%
|
Earnings before Tax (EBT)
1 |
-12.97
|
16.39
|
-28.35
|
-64.8
|
-3.883
|
-6.773
|
-14.5
|
-17.92
|
-18.81
|
-2.449
|
-8.638
|
-9.038
|
-9.425
|
-8.638
|
Net income
1 |
-13.15
|
14.7
|
-31.56
|
-69.96
|
-5.14
|
0.856
|
-16.46
|
-17.56
|
-19.31
|
-5.781
|
-12.11
|
-13.58
|
-14.7
|
-11.28
|
Net margin
|
-9.26%
|
10.17%
|
-33.35%
|
-74.07%
|
-5.72%
|
0.95%
|
-19.15%
|
-21.9%
|
-29.23%
|
-7.74%
|
-21.23%
|
-24.88%
|
-27.83%
|
-19.67%
|
EPS
2 |
-0.0300
|
0.0400
|
-0.0800
|
-0.1800
|
-0.0100
|
-
|
-0.0400
|
-0.0400
|
-0.0500
|
-0.0100
|
-0.0320
|
-0.0380
|
-0.0420
|
-0.0360
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/3/21
|
3/1/22
|
5/4/22
|
8/3/22
|
10/27/22
|
3/1/23
|
5/3/23
|
8/2/23
|
11/1/23
|
2/29/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
594
|
501
|
219
|
218
|
199
|
217
|
187
|
32
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-11.8
|
-22
|
-66.5
|
-181
|
6.88
|
21
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-5.95%
|
-2.91%
|
1.19%
|
-16.8%
|
-5.15%
|
-14.5%
|
-13.3%
|
-
|
ROA (Net income/ Total Assets)
|
-3.57%
|
-1.95%
|
0.76%
|
-10.8%
|
-3.44%
|
-9.52%
|
-8.33%
|
-
|
Assets
1 |
634
|
924.1
|
1,017
|
977.1
|
1,718
|
636.7
|
631.2
|
-
|
Book Value Per Share
2 |
1.780
|
1.640
|
1.680
|
1.480
|
1.350
|
1.210
|
1.120
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
2.48
|
0.25
|
-
|
0.6
|
-
|
0.5
|
0.5
|
0.5
|
Capex / Sales
|
0.58%
|
0.04%
|
-
|
0.16%
|
-
|
0.22%
|
0.22%
|
0.17%
|
Announcement Date
|
2/25/20
|
2/25/21
|
3/1/22
|
3/1/23
|
2/29/24
|
-
|
-
|
-
|
Mean consensus UNDERPERFORM Last Close Price
0.8749
USD Average target price
1.083
USD Spread / Average Target +23.82% Consensus |
1st Jan change
|
Capi.
|
---|
| +0.56% | 359M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|